Conventional chemotherapy for adult type soft tissue sarcomas is not very effective. Rarely are patients with advanced soft tissue sarcomas curable by systemic chemotherapy. Thus, the benefits from chemotherapy have been equivocal even when treatment is given postoperatively to patients whose primary sarcomas have been excised. Current research is directed toward the achievement of a high percentage of complete tumor regressions in patients with advanced metastatic disease in hope that this can be translated into truly effective adjuvant therapy. Several recent new approaches to systemic treatment for soft tissue sarcomas are assessed including prospects for possible enhancement of chemotherapy by agents which stimulate cellular immunity. Some unexpectedly favorable responses to chemotherapy + granulocyte-macrophage colony-stimulating factor (GM-CSF) in an ongoing study are discussed. (C) 1994 Wiley-Liss, Inc.
机构:
THOMAS JEFFERSON UNIV HOSP & MED COLL,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107THOMAS JEFFERSON UNIV HOSP & MED COLL,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107
MCCLAY, EF
SLOVIN, SF
论文数: 0引用数: 0
h-index: 0
机构:
THOMAS JEFFERSON UNIV HOSP & MED COLL,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107THOMAS JEFFERSON UNIV HOSP & MED COLL,JEFFERSON MED COLL,DEPT MED,PHILADELPHIA,PA 19107
机构:
Royal Marsden Hosp, Childrens & Young Peoples Unit, Sutton, Surrey, EnglandRoyal Marsden Hosp, Childrens & Young Peoples Unit, Sutton, Surrey, England